AU2020395111A1 - Engineering circular guide RNAs - Google Patents

Engineering circular guide RNAs Download PDF

Info

Publication number
AU2020395111A1
AU2020395111A1 AU2020395111A AU2020395111A AU2020395111A1 AU 2020395111 A1 AU2020395111 A1 AU 2020395111A1 AU 2020395111 A AU2020395111 A AU 2020395111A AU 2020395111 A AU2020395111 A AU 2020395111A AU 2020395111 A1 AU2020395111 A1 AU 2020395111A1
Authority
AU
Australia
Prior art keywords
rna
engineered
sequence
guide rna
engineered guide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020395111A
Other languages
English (en)
Inventor
Dhruva KATREKAR
Prashant MALI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Publication of AU2020395111A1 publication Critical patent/AU2020395111A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020395111A 2019-12-02 2020-12-01 Engineering circular guide RNAs Pending AU2020395111A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962942725P 2019-12-02 2019-12-02
US62/942,725 2019-12-02
US202063112492P 2020-11-11 2020-11-11
US63/112,492 2020-11-11
PCT/US2020/062748 WO2021113264A1 (en) 2019-12-02 2020-12-01 Engineering circular guide rnas

Publications (1)

Publication Number Publication Date
AU2020395111A1 true AU2020395111A1 (en) 2022-06-02

Family

ID=76221931

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020395111A Pending AU2020395111A1 (en) 2019-12-02 2020-12-01 Engineering circular guide RNAs

Country Status (7)

Country Link
US (1) US20230036370A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069830A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023504048A (cg-RX-API-DMAC7.html)
CN (1) CN115210366A (cg-RX-API-DMAC7.html)
AU (1) AU2020395111A1 (cg-RX-API-DMAC7.html)
CA (1) CA3159799A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021113264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3162908A1 (en) * 2019-12-03 2021-06-10 Beam Therapeutics Inc. Synthetic guide rna, compositions, methods, and uses thereof
IL293671A (en) * 2019-12-09 2022-08-01 Astellas Pharma Inc Antisense guide RNA with an additional functional region for target RNA editing
EP4158017A1 (en) * 2020-05-26 2023-04-05 Shape Therapeutics Inc. Engineered circular polynucleotides
EP4240338A4 (en) * 2021-01-04 2025-08-06 Univ California IN VIVO PROGRAMMABLE RNA EDITING BY RECRUITMENT OF ENDOGENOUS ADARS
JP2024504608A (ja) * 2021-01-12 2024-02-01 北京大学 遺伝子操作rnaを使用した内因性adarの活用による標的化rnaの編集
JP2024542983A (ja) * 2021-10-26 2024-11-19 シェイプ セラピューティクス インコーポレイテッド Rna編集組成物及び使用方法
EP4667570A1 (en) * 2024-06-20 2025-12-24 Johannes Gutenberg-Universität Mainz Nucleic acid molecule complex for target pseudouridylation in mammalian cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150299702A1 (en) * 2012-11-30 2015-10-22 Aarhus Universitet Circular rna for inhibition of microrna
CN106133138A (zh) * 2013-08-22 2016-11-16 先锋国际良种公司 使用引导多核苷酸/cas内切核酸酶系统的基因组修饰及其使用方法
AU2017283713B2 (en) * 2016-06-17 2021-04-08 Massachusetts Institute Of Technology Type VI CRISPR orthologs and systems
WO2018237372A1 (en) * 2017-06-23 2018-12-27 Cornell University RNA MOLECULES, METHODS FOR PRODUCING CIRCULAR RNA, AND METHODS OF TREATMENT
CN111328290A (zh) * 2017-06-26 2020-06-23 博德研究所 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法
US20200362334A1 (en) * 2017-12-07 2020-11-19 The Broad Institute, Inc. High-throughput methods for identifying gene interactions and networks
MX2020006150A (es) * 2017-12-15 2020-11-11 Flagship Pioneering Innovations Vi Llc Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
CN119193702A (zh) * 2018-09-06 2024-12-27 加利福尼亚大学董事会 经由改造的adar募集的rna和dna碱基编辑
AU2020313143B2 (en) * 2019-07-12 2024-04-04 Peking University Targeted RNA editing by leveraging endogenous adar using engineered RNAs
EP4158017A1 (en) * 2020-05-26 2023-04-05 Shape Therapeutics Inc. Engineered circular polynucleotides

Also Published As

Publication number Publication date
CA3159799A1 (en) 2021-06-10
JP2023504048A (ja) 2023-02-01
CN115210366A (zh) 2022-10-18
WO2021113264A1 (en) 2021-06-10
US20230036370A1 (en) 2023-02-02
EP4069830A4 (en) 2024-10-02
EP4069830A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
US20250270543A1 (en) Programmable rna editing in vivo via recruitment of endogenous adars
US20230036370A1 (en) Engineering circular guide rnas
US11963982B2 (en) CRISPR/RNA-guided nuclease systems and methods
US20240417706A1 (en) Systems and methods for the treatment of hemoglobinopathies
JP7720623B2 (ja) 遺伝子操作されたadarのリクルートを介したrna及びdna塩基の編集
US8309356B2 (en) Pseudocomplementary oligonucleotides for targeted gene therapy
EP3010514B1 (en) Double-stranded antisense nucleic acid with exon-skipping effect
AU2024205204A1 (en) Synthetic guide molecules, compositions and methods relating thereto
AU2014306416B2 (en) Compositions and methods for modulating RNA
TW202024324A (zh) 用於抑制17β-HSD第13型(HSD17B13)表現之RNAi藥劑、其組合物及使用方法
US20120149757A1 (en) Compositions and methods for modulation of smn2 splicing
TW202221120A (zh) 用於治療代謝症候群之組成物及方法
AU2022203361A1 (en) Compositions and methods for modulating RNA
TW202444910A (zh) 編碼casx之信使rna
US20200263206A1 (en) Targeted integration systems and methods for the treatment of hemoglobinopathies
WO2022248879A1 (en) Composition and method for adar-mediated rna editing
CN114901823A (zh) 诱导外显子50的跳读的反义核酸
CN115210376A (zh) 诱导外显子51的跳读的反义核酸
TW202444904A (zh) 用於抑制粒線體醯胺肟還原組分1(MARC1)之表現之RNAi藥劑、其醫藥組合物及使用方法
WO2026022136A1 (en) Antisense oligonucleotides for the treatment of metabolic disorders
WO2025128134A1 (en) Crispri targeting alpha-synuclein
WO2025061842A1 (en) Gene editing tgm1 mutations for treating autosomal recessive congenital ichthyosis (arci)
HK40078573A (en) Antisense nucleic acid that induces skipping of exon 50
HK40082220A (en) Antisense nucleic acid inducing skipping of exon 51